The clinical evaluation of novel imaging methods for cancer management

Nature Reviews Clinical Oncology

Volumn 9, Issue 12, 2012, Pages 738-744

  Shankar, Lalitha K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; COPPER DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; DEXAMETHASONE; DOCETAXEL; FERUMOXYTOL; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROTESTOSTERONE F 18; FLUOROESTRADIOL F 18; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE ESCALATION; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; UNITED STATES;

EID: 84870416028     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.186     Document Type: Review

References (65)

1. Histed, S. N. et al. Review of functional/anatomical imaging in oncology. Nucl. Med. Commun. 33, 349-361 (2012).
2. Butowski, N. & Chang, S. M. Endpoints for clinical trials and revised assessment in neurooncolgy. Curr. Opin. Neurol. http://dx.doi.org/10.1097/WCO. 0b013e328359b45e.
3. Paul, N. S., Ley, S. & Metser, U. Optimal imaging protocols for lung cancer staging: CT, PET, MR Imaging and the role of imaging. Radiol. Clin. North Am. 50, 935-949 (2012).
4. Shankar, L., Menkens, A. & Sullivan, D. in Molecular Targeting in Oncology (eds Kaufman, H. L., Wadler, S. & Antman, K.) 675-692 (Humana Press, Totowa, 2008).
5. Beyer, T. & Townsend, D. W. Putting 'clear' into nuclear medicine: A decade of PET/CT development. Eur. J. Nuc. Med. Mol. Imaging 33, 857-861 (2006).
6. Cerussi, A. E. et al. Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer adjuvant chemotherapy. Philos. Transact. A Math. Phys. Eng. Sci. 369, 4512-4530 (2011).
7. Vesselle, H et al. In vivo validation of 3'deoxy3'[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki67 immunohistochemistry and flow cytometry in human lung tumors. Clin. Cancer Res. 8, 3315-3323 (2002).
8. Dancey, J. E. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 16, 1745-1755 (2010).
9. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00362973 (2011).
10. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00588185 (2012).
11. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00569127 (2012).
12. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01507428 (2012).
13. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00572728 (2012).
14. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00963807 (2011).
15. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00794339 (2012).
16. Sargent, D. J. et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur. J. Cancer 45, 290-299 (2008).
17. Shankar, L. K. et al. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin. Cancer Res. 15, 1891-1897 (2009).
18. Nunn, A. Imaging biomarkers, an industry perspective J. Nucl. Med. 49, 28N-32N (2008).
19. US Department of Health & Human Services. NIH Research Project Grant Program (R01) [online], http://grants.nih.gov/grants/funding/r01.htm (2012).
20. US Department of Health & Human Services. NIH Exploratory/ Developmental Research Grant Award (R21) [online], http://grants.nih.gov/grants/ funding/r21.htm (2012).
21. Jansen, J. F. et al. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int. J. Radiat. Oncol. Biol. Phys. 77, 1403-1410 (2010).
22. Juhász, C. et al. Tryptophan metabolism in breast cancers: Molecular imaging and immunohistochemistry studies. Nucl. Med. Biol. 39, 926-932 (2012).
23. US Department of Health & Human Services. Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) [online], http://grants.nih.gov/grants/guide/pa-files/PAR-06-293.html.
24. US Department of Health & Human Services. Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) [online], http://grants.nih.gov/grants/guide/pa-files/PAR-08-147.html.
25. Boles Ponto, L. L. et al. Stability of 3'deoxy3'[18F]fluorothymidine standardized uptake values in head and neck cancer over time. Cancer Biother. Radiopharm. 25, 361-363 (2010).
26. Breshears, J. D. et al. Mapping sensorimotor cortex with slow cortical potential resting-state networks while awake and under anesthesia. Neurosurgery 71, 305-316 (2012).
27. Wali, R. K. et al. Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response. PLoS One 7, e38047 (2012).
28. US Department of Health & Human Services. Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21) [online], http://grants.nih. gov/grants/guide/pa-files/PAR-11-216.html.
29. National Cancer Institute. Translational Research Program (TRP) [online], http://trp.cancer.gov/.
30. National Cancer Institute. Cancer Imaging Program: Phase I/II Trials [online], http://imaging.cancer.gov/clinicaltrials/earlyphase.
31. Spence, A. M. et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'deoxy3'[(18)F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: Preliminary efficacy studies. Mol. Imaging Biol. 11, 343-355 (2009).
32. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01169350 (2011).
33. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00087347 (2006).
34. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00559377 (2010).
35. National Cancer Institute. Cancer Therapy Evaluation Program: Initiatives/Collaborations [online], http://ctep.cancer.gov/ industryCollaborations/default.htm#initiatives (2012).
36. National Cancer Institute. Cancer Imaging Program: Cancer Tracer Synthesis Resources [online], http://imaging.cancer.gov/programsandresources/ Cancer-Tracer-Synthesis-Resources.
37. American College of Radiology Imaging Network. ACRIN's History [online], http://www.acrin.org/researchers/aboutacrin/acrinhistory.aspx.
38. American College of Radiology Imaging Network [online], http://www.acrin.org/home.aspx (2012).
39. National Cancer Institute. Transforming the NCI Clinical Trials Enterprise [online], http://transformingtrials.cancer.gov/steering/clinical- imaging.
40. National Cancer Institute. Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP) [online], http://biqsfp.cancer.gov.
41. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00884741 (2011).
42. Shankar, L. K. Standardization of PET imaging in clinical trials. PET Clinics 3, 1-4 (2008).
43. Shankar, L. K. et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J. Nucl. Med. 47, 1059-1066 (2006).
44. American College of Radiology Imaging Network. NCI Centers of Quantitative Imaging Excellence [online], http://www.acrin.org/corelabs/ ncicqiequalificationprogram.aspx (2012).
45. Trimble, E. L. et al. Improving cancer outcomes through international collaboration in academic cancer treatment trials J. Clin. Oncol. 27, 5109-5114 (2009).
46. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
47. Ford, R. et al. Lessons learned from independent central review. Eur. J. Cancer 45, 268-274 (2009).
48. Dancey, J. E. et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur. J. Cancer 45, 281-289 (2009).
49. Schwartz, L. H. et al. Evaluation of lymph nodes with RECIST 1.1. Eur. J. Cancer. 45, 261-267 (2009).
50. Radiological Society of North America. Quantitative Imaging Biomarkers Alliance [online], http://www.rsna.org/QIBA.aspx (2012).
51. Clinical Trials Network [online], http://interactive.snm.org/index.cfm? PageID=8813 (2012).
52. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00276770 (2012).
53. Spence, A. M. et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety studies. Mol. Imaging Bio. 10, 271-280 (2008).
54. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/study/NCT00087347 (2011).
55. Harisinghani, M., Ross, R. W., Guimaraes, A. R. & Weissleder, R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 9, 1160-1165 (2007).
56. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/study/NCT00362973 (2011).
57. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00083083 (2011).
58. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/record/NCT01507428 (2012).
59. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/study/NCT01333033 (2012).
60. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00416455 (2012).
61. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01296139 (2012).
62. Batchelor, T. T. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28, 2817-2823 (2010).
63. Gerstner, E. R. et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 12, 466-472 (2010).
64. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00305656 (2011).
65. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00769093 (2012).